# An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

> **NCT01384162** · PHASE1,PHASE2 · TERMINATED · sponsor: **Newron Sweden AB** · enrollment: 15 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** sNN0029

## Key facts

- **NCT ID:** NCT01384162
- **Lead sponsor:** Newron Sweden AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Issues with development and supply of infusion system for delivery of IMP. Lack of favorable benefit risk ratio in sNN0029-003 study (review of interim data).
- **Last updated:** 2016-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01384162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01384162, "An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01384162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*